Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Wolverine Stack (BPC-157 + TB-500)22 residues (approx.)GEPPPGKPADDAGLVLKKTETQEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: Wolverine Stack, BPC-157/TB-500 blend, healing stack
Fourteen out of sixteen knee pain patients reported significant relief at six to twelve months in the only published human data on this combination (Lee and Padgett 2021, referenced in)[1]. The Wolverine Stack is a pre-mixed blend of BPC-157 (5 mg) and TB-500 (5 mg) in a single vial. BPC-157 targets local tissue repair through angiogenesis and receptor upregulation. TB-500 handles the systemic side, driving cell migration and reducing inflammation body-wide. Formal clinical trials on the blend itself don't exist yet. Community evidence from tens of thousands of users fills that gap with remarkably consistent healing reports. Athletes, post-surgical patients, and anyone with a stubborn soft tissue injury gravitate to this stack first.
Does combining BPC-157 and TB-500 actually produce better healing than either peptide alone? The community figured this out before the researchers did. The Wolverine Stack (BPC-157 + TB-500, also called the healing stack) is a pre-mixed 10 mg vial containing 5 mg of each component. BPC-157 is a 15-amino acid fragment of body protection compound, a protein found in human gastric juice. TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) of thymosin beta-4, a 43-amino acid protein involved in cell migration. The two peptides work through different but complementary mechanisms. BPC-157 upregulates VEGFR2 and FGFR1 receptors at the injury site, promotes angiogenesis, and modulates the nitric oxide system. TB-500 sequesters G-actin, upregulates VEGF 2.5 to 3.8-fold, and drives cell migration systemically. You don't need to inject TB-500 near the injury; it distributes body-wide. One retrospective clinical report tested the combination in 16 knee pain patients. Fourteen of sixteen reported significant pain relief at 6 to 12 months (Lee and Padgett 2021, referenced in)[1]. Beyond that, evidence comes from the individual components: over 180 published BPC-157 papers (35 of 36 meeting systematic review criteria were animal studies per Vasireddi et al.)[2] and a Phase I human safety study on recombinant thymosin beta-4 [3]. Community evidence is strong. Tens of thousands of user reports across r/Peptides, ExcelMale, and Longecity consistently describe accelerated soft tissue healing within 2 to 4 weeks. The Wolverine Stack is considered the gold standard healing combination. Both components are classified as FDA-prohibited bulk drug substances and cannot be legally compounded at U.S. pharmacies.
Two repair systems working different angles from one syringe. BPC-157 acts at the injury site. It upregulates growth factor receptors VEGFR2 and FGFR1, triggering local angiogenesis. Sikiric and colleagues mapped its nitric oxide modulation in animal models [4], showing BPC-157 stabilizes NO pathways that support tendon-to-bone healing and gastric mucosal protection. TB-500 operates systemically. Its core mechanism is actin sequestration. By binding monomeric G-actin, TB-500 regulates cytoskeletal dynamics that control how quickly cells migrate to injury sites. Malinda and colleagues confirmed TB-500 increased reepithelialization by 42% at day 4 and 61% at day 7 versus controls in wound healing models [5]. TB-500 also upregulates VEGF 2.5 to 3.8-fold and reduces pro-inflammatory cytokine signaling. It inhibits myofibroblast differentiation, which decreases fibrosis and scar tissue formation. The combination rationale is additive rather than redundant. BPC-157 handles precision repair at the injection site; TB-500 sends repair signals body-wide regardless of where you inject. Animal models support the additive angiogenic effect. No human pharmacokinetic study exists for the blend.
No published RCT or clinical trial specifically tests the BPC-157 + TB-500 combination as a pre-mixed formulation. One retrospective clinical report (Lee & Padgett 2021, referenced in, n=16 knee pain patients)[1] used BPC-157 + thymosin beta-4 combined; 14/16 reported significant pain relief at 6–12 months: the only published human data on the combination. Individual component science is largely preclinical: over 180 papers on BPC-157 (35 of 36 meeting systematic review inclusion were animal studies; Vasireddi et al.)[2]. TB-500 has one published Phase I human safety study (rhTβ4)[3]. The combined Wolverine Stack has no dedicated human trial. Mechanistic rationale for synergy is supported: BPC-157 acts locally (VEGFR2/FGFR1 upregulation, angiogenesis, nitric oxide modulation) while TB-500 acts systemically (actin sequestration, cell migration, VEGF upregulation). Combined angiogenic effect is additive in animal models.
Lee & Padgett 2021 (retrospective, n=16, knee pain): referenced in PMID 40789979; 14/16 significant pain relief at 6–12 months. Only published human data combining BPC-157 with thymosin beta-4. Not indexed as standalone PMID.
No dedicated RCT. Only one retrospective human combination report (n=16, not indexed). All other evidence is animal-based. No human dose-finding or PK study for the blend. Ratio locked at 1:1 in pre-mixed vials prevents independent component titration. Combination angiogenic safety (pro-tumor vascularization risk) has not been evaluated in humans.
Strong community consensus. The Wolverine Stack is one of the most established peptide combinations. Tens of thousands of users report consistent outcomes. Protocol agreement is high across r/Peptides, ExcelMale, and practitioner guides. Considered the gold standard healing stack.
Science supports both individual components via preclinical evidence and one retrospective human combination report. Community protocol is mechanistically coherent with published science. Divergence exists on: (1) optimal dosing: community uses fixed 1:1 ratio from pre-mixed vial while science would support independent component titration; (2) loading structure: community adds TB-500-style loading to a daily BPC-157 protocol; (3) confidence ceiling: community treats this as well-established while evidence is still primarily animal-based.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | Daily |
| Moderate | 1mg | Daily |
| Aggressive | 1,500mcg | 2x Daily |
The dosing math on a 10 mg pre-mixed vial (5 mg BPC-157 + 5 mg TB-500) reconstituted with 2 mL bacteriostatic water: 5,000 mcg/mL total (2,500 mcg/mL each component). On a U-100 insulin syringe: 5 units = 250 mcg total, 10 units = 500 mcg total, 20 units = 1,000 mcg total. Start at the beginner dose (500 mcg/day, which is 10 units). Most people tolerate it without issues. If nausea hits, drop to 5 units for a few days and work back up. Inject as close to the injury as you can safely reach subcutaneously. For deeper structures like Achilles or rotator cuff, inject into subcutaneous tissue directly above. BPC-157 benefits from proximity; TB-500 goes everywhere regardless. One thing beginners miss: product quality matters more with blends. Require LC-MS/MS confirmation that both BPC-157 (MW 1419.5 Da) and TB-500 (MW 846.97 Da) are present at correct masses. HPLC alone can't distinguish closely related impurities in peptide blends.
Loading phase: full dose daily for 4-6 weeks. Then maintenance: half dose every other day. The TB-500 component benefits from a loading protocol.
Both components individually are cycled 6 weeks on / 2 weeks off by community consensus. The rationale is: (1) TB-500 loading structure (higher dose for 4–6 weeks, then maintenance or rest) follows a standard loading protocol for peptides with systemic accumulation; (2) BPC-157 theoretical receptor desensitization: no formal data but consistent with peptide receptor downregulation principles; (3) safety monitoring: the 2-week off period allows assessment of any adverse effects before re-loading; (4) no published long-term human safety data exists for either component beyond a few weeks. The combined cycle follows whichever component has the more conservative cycling requirement.
Or use the universal Peptide Calculator for any peptide.
Expected: Pain reduction and improved function within 2–4 weeks; significant healing by week 6. Community reports ~70–80% of users notice meaningful improvement within one loading cycle.
Monitor: Monitor for anxiety, palpitations (BPC-157 dopamine modulation). Watch for signs of healing overshooting: increased local swelling or warmth after week 4 can indicate excessive angiogenesis response.
Aim the stream along the glass wall. Do not shake. Swirl gently until dissolved (2 to 3 minutes). This gives you 5,000 mcg/mL total.
Draw your dose with a U-100 insulin syringe (29 to 31 gauge). Beginner: 10 units = 500 mcg total (250 mcg each component). Moderate: 20 units = 1,000 mcg total. Aggressive: 30 units = 1,500 mcg total.
Abdomen (two inches from navel), thigh, or subcutaneous tissue directly above the injury. BPC-157 works best locally.
Insert the needle at a 45-degree angle. Push the plunger slowly. Release the skin, withdraw the needle, apply light pressure.
If injecting near an injury, alternate between two spots on opposite sides of the affected area.
For the twice-daily advanced protocol, space injections 8 to 12 hours apart.
Store the reconstituted vial in the refrigerator at 2 to 8 degrees C. Use within 3 to 4 weeks. Never freeze reconstituted solution.
BPC-157 alone is acid-stable and used orally for gut healing at 500 mcg. However, the TB-500 component has no established oral bioavailability: it would be degraded in the GI tract. For oral gut healing, standalone BPC-157 is required; the pre-mixed vial should not be used orally.
If the goal is gut healing specifically, use standalone BPC-157 oral. The Wolverine Stack pre-mixed vial is subcutaneous only.
Same dose, different absorption kinetics. BPC-157 benefits from proximity to injury (SQ preferred). TB-500 is fully systemic regardless of route.
IM injection acceptable if preferred. Glute or deltoid common sites. SQ is preferred for the blend because BPC-157 local healing effect is preserved.
Copper peptide adds collagen synthesis, ECM remodeling, and skin/connective tissue repair on top of the angiogenic healing provided by BPC-157 + TB-500. The canonical advanced healing trio is BPC-157 (local angiogenesis), TB-500 (systemic migration), and GHK-Cu (collagen quality).
SQ or topical, daily, alongside Wolverine Stack injection
Potent anti-inflammatory tripeptide (α-MSH fragment). Reduces systemic inflammation that can impede healing. Stacked to address the inflammatory component while BPC-157 and TB-500 handle structural repair.
SQ daily or oral
GHRH analogue increases IGF-1 signaling, supporting satellite cell repair and muscle protein synthesis alongside the structural healing from the Wolverine Stack. Commonly combined as the "complete recovery stack."
Evening SQ injection, separate from Wolverine Stack
GHRP-2 analogue paired with CJC-1295 for pulsatile GH release and IGF-1 support. Adds anabolic recovery signaling to complement the Wolverine Stack healing mechanisms.
Evening SQ injection paired with CJC-1295
Directly opposes the angiogenic mechanism of both BPC-157 (VEGFR2 upregulation) and TB-500 (VEGF upregulation 2.5–3.8x). Combining nullifies both peptide effects and may produce unpredictable vascular signaling.
Do not combineBPC-157 modulates serotonin and dopamine pathways (PMID 9073154, animal data). Multiple community reports of worsened anxiety and panic attacks when combining BPC-157 with antidepressants. No human interaction study exists but mechanism is plausible. Discuss with prescriber.
Both BPC-157 and TB-500 promote angiogenesis, which may increase bleeding risk at healing sites. The combination amplifies this concern vs. either peptide alone.
TB-500 modulates immune cell migration; BPC-157 modulates leukocyte recruitment. Combined effect on immunosuppressive therapy is unknown. Theoretical risk of undermining therapeutic immunosuppression.
Pricing updated 2026-04-09
The most serious safety concern with the Wolverine Stack is its pro-angiogenic load. Both BPC-157 and TB-500 promote new blood vessel formation through different receptor pathways. In someone with an undiagnosed or subclinical tumor, that combined vascularization signal could theoretically support cancer growth. No human oncogenic data exists for either peptide, but the mechanism is real. Cancer screening before starting any cycle is not optional. Anxiety and panic attacks affect a subset of users. BPC-157 modulates serotonin and dopamine pathways (Sikiric et al., animal data)[4]. Multiple community reports describe worsened anxiety when combining BPC-157 with SSRIs or SNRIs. Users on antidepressants should discuss this with their prescriber before starting. If anxiety occurs, reducing to 250 mcg total per day or discontinuing the BPC-157 component specifically is the standard community approach. The TB-500 component alone does not trigger this effect. Heart palpitations are transient and most common in the first few days. They typically resolve without intervention. Nausea is the most frequently reported side effect overall. The BPC-157 component increases gastric motility, and higher doses make it worse. Injecting before bed rather than morning helps for most users. If nausea persists past week 2, suspect product quality; mannitol filler and residual acetonitrile from HPLC purification are common culprits in research-grade vials. "Peptide flu" hits some users in weeks one and two: malaise, chills, transient fatigue. This usually resolves by week three. Headaches during loading are attributed to vasodilation from the combined angiogenic response. Injection site reactions (redness, lumps, nodules) are often caused by benzyl alcohol in bacteriostatic water rather than the peptides themselves. Switching to preservative-free sterile water reduces reactions but shortens reconstituted shelf life. Any lump larger than 1 cm persisting beyond week two warrants medical evaluation. Human safety data is extremely limited. Total published human evidence for the combination is one retrospective report of 16 patients (Lee and Padgett 2021). TB-500 has one Phase I safety study [3]. BPC-157 has no completed human safety trial. Third-party testing has found inconsistent purity and labeling among peptide vendors. Pre-mixed blends face additional risk: if either component is compromised, the entire vial is affected. Contraindications: active cancer or cancer history, pregnancy or breastfeeding, active systemic infections, and known hypersensitivity to BPC-157, thymosin beta-4, or formulation components. When to stop: fever above 100.4 degrees F, rash, hives, worsening palpitations, severe anxiety, any sign of infection spreading. Do not push through these symptoms.
Verify Wolverine Stack (BPC-157 + TB-500) dosing and safety with a second opinion
Both BPC-157 and TB-500 are FDA-prohibited from licensed compounding. All available product is from unregulated research chemical vendors. A 2025 purity audit found 68% of peptide products mislabeled or containing impurities (Finnrick Analytics, 450 samples, 64 vendors). Pre-mixed blends face additional quality risk: if either component is contaminated or misdosed, the entire vial is compromised. No FDA-regulated compounded source exists as of April 2026.
| Test | When | Target |
|---|---|---|
| Cancer screening (clinical exam, PSA if male) | Before starting any cycle | No active malignancy confirmed before proceeding |
| Complete blood count (CBC) + comprehensive metabolic panel (CMP) | Baseline before starting; repeat at week 8 for cycles >6 weeks | — |
| Injection site inspection | Before each injection | — |
Both BPC-157 and TB-500 promote angiogenesis. Combined pro-angiogenic load could theoretically support vascularization of subclinical tumors. Strong contraindication in anyone with active cancer or history.
No specific BPC-157/TB-500 combination toxicity markers are established. Baseline provides reference for any unexpected changes in hepatic, renal, or hematologic parameters during use.
Nodules, blistering, or increasing redness at prior injection sites may indicate reaction to formulation excipients or early infection. TB-500-related site reactions are more common during loading phase.
Loading phase begins. Mild improvements in pain and inflammation may be noticed. BPC-157 begins local repair signaling while TB-500 reduces systemic inflammation.
Noticeable improvement in pain levels, flexibility, and range of motion. Angiogenesis accelerates tissue repair at the injury site.
Significant healing progress. Many users report substantially reduced pain and improved function. End of loading phase.
Transition to maintenance dosing. Continued healing support. Reload at full dose if a new injury occurs.
Days 1 through 7 (Onset and Systemic Distribution): BPC-157 plasma half-life runs under 30 minutes, but functional receptor upregulation begins within hours. TB-500 distributes systemically from the first injection. Many users pick up a slight reduction in acute pain by day three to five. Some report warmth or tingling at the injury site. Others feel nothing the first week. Nausea, mild headache, and the so-called "peptide flu" (malaise, chills) are most common during this window. Weeks 2 through 3 (Early Structural Response): Angiogenesis kicks in. TB-500 VEGF upregulation (2.5 to 3.8-fold) is detectable by week two in animal models, driving new capillary networks at injury sites. Most users land on their first real improvement here: less pain, better flexibility, early range-of-motion gains. Acute injuries respond faster than chronic ones. Side effects from week one typically fade. Weeks 4 through 6 (Peak Loading Phase): Peak collagen deposition and tissue remodeling hit their stride in preclinical models. TB-500 reepithelialization data shows a 61% increase at day 7 versus controls (Malinda et al.)[5]. The majority of users report real functional improvement. Athletes often return to modified training. Chronic conditions show progress but don't always fully resolve in one cycle. Weeks 7 through 8 (Maintenance or Off-Ramp): Users drop to half-dose or every-other-day frequency. Many stop entirely and assess. Some find the results stick; injury healed, no regression. Complex injuries (ACL, rotator cuff) may need a second loading cycle after two to four weeks off. TB-500 functional tissue activity persists 7 to 10 days per half-life data, so spacing out maintenance doses is reasonable.
BPC-157 plasma half-life <30 minutes; functional activity via receptor upregulation begins within hours of first dose. TB-500 distributes systemically, reaching injury sites regardless of injection location.
Many users notice slight reduction in acute pain and inflammation by day 3–5. Some report "warmth" or tingling at the injury site: attributed to initial angiogenesis signaling. Others feel nothing for the first week.
Angiogenesis begins generating new capillary networks at injury sites. TB-500 VEGF upregulation (2.5–3.8x) is detectable by week 2 in animal models. Cell migration to damaged areas accelerates.
Most users report their first significant improvement here: pain reduction, improved flexibility, and early range-of-motion restoration. Acute injuries show faster response than chronic.
Peak collagen deposition and tissue remodeling phase in preclinical models. TB-500 reepithelialization +61% at day 7 in wound models (Malinda et al. PMID 10469335): comparable systemic support active.
Majority of users report significant functional improvement. Athletes often return to modified training. Pain substantially reduced or eliminated for acute injuries. Chronic conditions showing improvement but not always complete resolution.
Continued receptor desensitization possible with daily dosing. TB-500 maintenance dosing rationale: tissue activity persists 7–10 days per half-life data. No published tolerance data for the combination.
Users transition to half-dose or every-other-day maintenance. Many stop entirely and assess. Some report results "locked in": injury healed, no regression after stopping. Complex injuries (ACL, rotator cuff) may need a second cycle.
Source: Estimated from component half-lives: BPC-157 plasma t1/2 ~30 min (functional ~4h), TB-500 plasma t1/2 ~5h. Blend half-life reflects the shorter-acting component for dosing purposes.
Loading the interactive decay curve.
BPC-157 and TB-500 were both on the FDA Category 2 bulk drug substance list until April 15, 2026, when HHS removed them along with 11 other peptides. Licensed U.S. compounding pharmacies cannot yet produce either component or the pre-mixed blend. PCAC review begins July 2026, with compounding access projected for late 2026 to mid-2027. All currently available Wolverine Stack product comes from unregulated research chemical vendors. It is sold labeled "for research purposes only" and is not approved for human use by the FDA or any regulatory agency. TB-500 (thymosin beta-4 fragments) is banned by WADA under S2: Growth Factors, both in and out of competition. Athletes subject to anti-doping testing should not use this product. This content is for informational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
